Boston Scientific's WATCHMAN FLX Pro trial meets primary endpoints
Bitget2026/11/02 19:04- Boston Scientific reported positive six-month primary results from the SIMPLAAFY trial of its WATCHMAN FLX Pro left atrial appendage closure device.
- Aspirin alone and reduced-dose anticoagulant regimens matched dual antiplatelet therapy for stroke protection, with less bleeding, supporting simpler post-implant treatment.
- The reduced-dose anticoagulant regimen also showed fewer device-related blood clots than dual antiplatelet therapy.
- Results were presented at Transcatheter Cardiovascular Therapeutics 2026 and simultaneously published in JAMA.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
SpaceX (SPCX.US) undergoes board changes: Google executive departs, Tesla merger evaluation underway.
SpaceX (SPCX.US) announced on Friday that Don Harrison has resigned from the company's board of directors.
Crypto prices
More
